Lucienne C. F. F.
- Country
- Spain
- Department
- Departamento de Neurología
Research Overview
- Phase III Open‑Label Single‑Arm Multicenter Study of On‑Body Delivery System for Subcutaneous High‑Concentration Ocrelizumab in Adults with Multiple Sclerosis
- Non-Inferiority Study of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Multiple Sclerosis Patients Over Two Years
- Long-term Safety and Efficacy Evaluation of Ocrelizumab in Multiple Sclerosis Patients from Phase III Studies
Data & Insights
Has run more than one trial at 203 of 372 partner sites.
Specializations
Multiple Sclerosis Treatment Innovation
The investigator specializes in conducting research on various therapeutic approaches for multiple sclerosis (MS), with particular emphasis on both relapsing and progressive forms of the condition.
- Novel therapeutic agents evaluation
- Long-term safety assessment
- Comparative treatment efficacy
Their research encompasses both established and emerging MS therapies, including monoclonal antibodies and targeted molecular treatments.
Specialized Population Studies
The investigator focuses on developing treatment strategies for specific patient populations, including pediatric MS patients and those with primary progressive multiple sclerosis (PPMS).
- Pediatric MS treatment optimization
- Progressive MS management
- Treatment-naïve patient care
Their work includes evaluating treatment responses in newly diagnosed patients and those with various disease subtypes.
Advanced Therapeutic Approaches
The investigator explores innovative treatment modalities including CAR T-cell therapy and combination therapeutic strategies for multiple sclerosis.
- Immunotherapy development
- Combination treatment protocols
- Disease modification strategies
Their research extends to investigating novel therapeutic mechanisms and treatment delivery methods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.